Promising Adventitia in Atherosclerosis.

IF 2.8 3区医学 Q2 PERIPHERAL VASCULAR DISEASE Current vascular pharmacology Pub Date : 2025-01-13 DOI:10.2174/0115701611306375241211084246

Maolin Qiao, Ruijing Zhang, Xuezhen Xuan, Sheng Yan, Honglin Dong

引用次数: 0

Abstract

The adventitia, the artery's most intricate layer, has received little attention.. During atherosclerosis, adventitia components undergo significant changes, such as angiogenesis, lymphangiogenesis, Artery Tertiary Lymphoid Organ (ATLO) formation, axon density increase, fibroblast activation, and stem cell differentiation. The reasons behind these changes and their contribution to atherosclerosis are beginning to be understood. In this review, we summarize the adventitia components and their role in normal arteries and then discuss the changes, pathogenesis, and potential clinical application of the adventitia in atherosclerosis.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

动脉粥样硬化中的有希望的血管内膜。

动脉最复杂的外膜很少受到关注。动脉粥样硬化期间，外膜成分发生显著变化，如血管生成、淋巴管生成、动脉三级淋巴器官（ATLO）形成、轴突密度增加、成纤维细胞激活和干细胞分化。这些变化背后的原因及其对动脉粥样硬化的影响正在开始被理解。本文综述了动脉外膜的组成及其在动脉粥样硬化中的作用，并讨论了动脉外膜在动脉粥样硬化中的变化、发病机制和潜在的临床应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current vascular pharmacology 医学-外周血管病

CiteScore

9.20

自引率

4.40%

发文量

审稿时长

6-12 weeks

期刊介绍： Current Vascular Pharmacology publishes clinical and research-based reviews/mini-reviews, original research articles, letters, debates, drug clinical trial studies and guest edited issues to update all those concerned with the treatment of vascular disease, bridging the gap between clinical practice and ongoing research. Vascular disease is the commonest cause of death in Westernized countries and its incidence is on the increase in developing countries. It follows that considerable research is directed at establishing effective treatment for acute vascular events. Long-term treatment has also received considerable attention (e.g. for symptomatic relief). Furthermore, effective prevention, whether primary or secondary, is backed by the findings of several landmark trials. Vascular disease is a complex field with primary care physicians and nurse practitioners as well as several specialties involved. The latter include cardiology, vascular and cardio thoracic surgery, general medicine, radiology, clinical pharmacology and neurology (stroke units).